precisionmedicineonline10h
Immuneering Partners with Regeneron to Study Combined MEK, PD-1 Inhibitor Therapy in Solid Tumors
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
BioSpace19h
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
yonkerstimes1d
Hackley Student Vivek Malik Named a Finalist in Regeneron Science Talent Search
Congratulations to Vivek Malik who was named a Regeneron Science Talent Search 2025 finalist. Vivek is a student at The ...
Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...
The Journal News3d
New science research fair set for middle schoolers from Westchester, Rockland, Putnam
A new in-person science and engineering research fair for middle school students from Westchester, Rockland and Putnam counties will premier on Saturday, April 26 at Edgemont High School. The ...
Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...